ARCHIVE # 4: 554 ARTICLES (NOV -SEPT 2006)
Dr. Timothy L. Vollmer


Chairman, Division of Neurology

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
My Educational Video on MS and MS Trials
Produced by www.MDhealthChannel.com
UNDER CONSTRUCTION
Visitors Since 03/2006
Click here to read messages from our MySpace Friends
HERE'S A FEW OF OUR 1,404 MySpace FRIENDS
CLICKING ON THE RED BUTTON BELOW COULD SAVE TOUR LIFE IF THERE'S A PROBLEM WITH A MS DRUG!
WE WILL SEND YOU BREAKING NEWS ON MS DRUGS IF YOU CLICK ON THE RED BUTTON BELOW.....Scroll down & read what we did last year...within 24 hours of the 1st death from Tysabri!
IMPORTANT: We filmed the video below within hours of the 1st death from Tysabri and e-mailed it to everyone who clicked the Flashing Red Button above!...WATCH THE VIDEO...THEN CLICK THE FLASHING RED BUTTON ABOVE!
Timothy L. Vollmer M.D.
Chairman, Division of Neurology
Barrow Neurological Institute
St. Joseph's Hospital and Medical Center


BARROW NEUROLOGICAL INSTITUTE'S
GRAND CANYON
RIM-RIM-HIKE


Organized by Dr. Robert F. Spetzler - Director, Barrow Neurological Institute

250 Photo-Slideshow


Click to view 1280 MS Walk photos!

"Join a trial at Barrow & receive all medication & study based procedures at no charge!"
Stan Swartz, CEO, The MD Health Channel

"WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!"
Simply click the "video" buttons below:

.

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

"OUR TEAM IS WORKING ON A CURE FOR MS"
Runtime: 54 sec
Runtime: 54 sec
Susan N. Rhodes
Multiple Sclerosis Research
Barrow Neurological Institute

"'The 2006 Barrow Neurological Institute at St. Joseph's Hospital MS "Walk on the Wild Side" raised more than $460,000 with 3,500 walkers! Click on the blue link above to view photos"

Chris Uithoven
President
National Multiple Sclerosis Society
Arizona Chapter


"THE MS SOCIETY OFFERS MANY PROGRAMS TO HELP...EVERYTHING FROM PILATES & SUPPORT GROUPS TO HORSEBACK RIDING"
Jerry Turner
Program Director
National Multiple Sclerosis Society
Arizona Chapter

Previious Posts

MS NEWS ARCHIVES: by week
September 2006  
October 2006  
November 2006  
July 2013  
April 2014  

This page is powered by Blogger. Isn't yours?

Saturday, November 04, 2006

 

cladribine...FDA also approves fast-track testing of drug for MS treatment....BYU News Release
Brigham Young University researchers have developed an improved method for making a drug called "" that has proven effective against certain types of cancer, including hairy cell leukemia, which affects as many as 800 patients a year.

In related news, pharmaceutical company Serono recently received "fast-track" status by the Food and Drug Administration for testing its new oral cladribine treatment for multiple sclerosis, which affects 2 million people worldwide.

Morris J. Robins, the J. Rex Goates Professor of Chemistry, led BYU's efforts to devise the more effective way of synthesizing cladribine.

Joined by graduate student Minghong Zhong and postdoctoral fellow Ireneusz Nowak, Robins published his laboratory's improved method this fall in The Journal of Organic Chemistry.

"It's very gratifying to know that something we do in the laboratory may be used to improve the condition of others," said Robins, whose past research and discoveries have contributed to the fight against AIDS and hepatitis B.

Arthur D. Broom, professor of medicinal chemistry and associate dean for research at the University of Utah's College of Pharmacy, said that Robins is one of the world leaders in the area of nucleoside chemistry. Nucleosides are the building blocks of DNA and RNA, which carry a person's genetic information.

"A problem with cladribine and many similar drugs is that they are very difficult and expensive to make, largely because the chemical syntheses involved result in the formation not of just the desired drug, but several related, but useless, chemical compounds," said Broom.

"Dr. Robins has found a novel, relatively inexpensive and highly specific way to eliminate the formation of these unwanted byproducts, giving the pure cladribine as the sole compound," added Broom. "This is a very significant advance in making important drugs available at reasonable cost."

BYU's new patent-pending method may be of interest to pharmaceutical companies that produce cladribine.

"A good method to synthesize cladribine is important for industries that produce this compound, and even more important to the patients that need the drug for treatment," said Herdewijn. "Dr. Robins' methodology has no precedent in the field and brings the technology near to perfection."